Blanket Purchase Agreement 36F79723D017E-36E79723A0010
Award Date
1/20/23
Last Date to Order
7/14/23
Federal Agency
National Acquisition Center
Awardee
Provention Bio Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The National Acquisition Center, a civilian agency within the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Provention Bio Inc. to provide the pharmaceutical product TZIELD. The $5 million BPA has a period of performance through June 2024 and is one of two BPAs awarded against Provention Bio's existing $5 million Federal Supply Schedule 65 I B contract, which was initially awarded in July 2023 for a 5-year term. An additional $1.44 million BPA was...
The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
Provention Bio Inc. was awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products by the Department of Veterans Affairs (VA) VISN 12 in July 2023. This multiple-award IDIQ contract vehicle allows federal agencies to issue task orders for these products as needed. Additionally, the VA National Acquisition Center awarded two Blanket Purchase Agreements (BPAs) to Provention Bio against this FSS contract. The...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) to Regeneron Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer. The BPA, which falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), has a ceiling value of $780,000.00 and an ultimate completion date of September 29, 2025. The primary product being procured under this BPA is the drug EVKEEZA. A firm fixed-price BPA Call Order was issued on November 24, 2021 with a...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025. The VA Greater Los Angeles Healthcare System...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025. The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...
The Blanket Purchase Agreement was awarded as a single-award contract by the Department of Veterans Affairs National Acquisition Center on April 14, 2022. The agreement is with Calliditas Therapeutics US Inc. to provide TARPEYO for a potential value of $1,750,000.00. TARPEYO is a treatment for the uncontrolled proteinuria in adult patients with primary immunoglobulin A nephropathy. As a single-award BPA with no set-aside, Calliditas Therapeutics will serve as the sole provider of this...